%0 Journal Article
%T Transfusion burden in non-dialysis chronic kidney disease patients with persistent anemia treated in routine clinical practice: a retrospective observational study
%A Kathleen M Fox
%A Jerry Yee
%A Ze Cong
%A John M Brooks
%A Jeffrey Petersen
%A Lois Lamerato
%A Shravanthi R Gandra
%J BMC Nephrology
%D 2012
%I BioMed Central
%R 10.1186/1471-2369-13-5
%X A retrospective cohort study of electronic medical record data from the Henry Ford Health System identified 374 adult, ND-CKD patients with severe anemia (Hb < 10 g/dL and subsequent use of erythropoiesis-stimulating agents [ESA] therapy, blood transfusions, or a second Hb < 10 g/dL) between January 2004 and June 2008. Exclusions included those with prior diagnoses of cancer, renal or liver transplant, end-stage renal disease, acute bleeding, trauma, sickle cell disease, or aplastic anemia. A gap of ¡Ý 1 days between units of blood transfused was counted as a separate transfusion.At least 1 transfusion (mean of 2 units; range, 1-4) was administered to 20% (75/374) of ND-CKD patients with mean (¡À SD) follow-up of 459 (¡À 427) days. The mean (¡À SD) Hb level closest and prior to a transfusion was 8.8 (¡À 1.5) g/dL. Patients who were hospitalized in the 6 months prior to their first anemia diagnosis were 6.3 times more likely to receive a blood transfusion than patients who were not hospitalized (p < 0.0001). Patients with peripheral vascular disease (PVD) were twice as likely to have a transfusion as patients without PVD (p = 0.04).Transfusions were prevalent and the trigger hemoglobin concentration was approximately 9 g/dL among ND-CKD patients with anemia. To reduce the transfusion burden, clinicians should consider other anemia treatments including ESA therapy.Chronic kidney disease (CKD) affects about 26 million adults (11%) in the United States, with the early stages (stages 3-4) being approximately 100 times more prevalent than kidney failure [1]. Persistent anemia is a consequence of the declining endogenous erythropoietin production seen in progressive CKD [2]. Anemia of CKD can be successfully treated by administration of an erythropoiesis-stimulating agent (ESA) [3]. Blood transfusion in non-dialysis (ND) CKD occurs in nearly 10% of Medicare-insured CKD patients per year despite the availability of ESA therapy, a rate four times as great as in older patients wit
%U http://www.biomedcentral.com/1471-2369/13/5